NCT01220648View on ClinicalTrials.gov

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Nilotinib, interferon-alfa

Trial Locations (1)

04103

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01220648 - Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) | Biotech Hunter | Biotech Hunter